The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial evaluating tumor penetration of bortezomib in patients with recurrent malignant gliomas treated prior to surgery and then treated with bortezomib and temozolomide postoperatively.
Jeffrey J. Raizer
Research Funding - Millennium
Sean Aaron Grimm
No relevant relationships to disclose
Robert M. Levy
No relevant relationships to disclose
Kenji Muro
No relevant relationships to disclose
Joshua M. Rosenow
No relevant relationships to disclose
James Chandler
No relevant relationships to disclose
Markus Bredel
No relevant relationships to disclose